1. Pink Sheet

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

 
• By Cathy Kelly

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Express Scripts HQ

Indication-specific pricing may begin to reshape US reimbursement for anti-inflammatory drugs in the first half of 2017, when pharmacy benefit manager Express Scripts Holding Co. launches its new approach to contracting.

In a move away from paying for anti-inflammatory drugs as a broad category, Express Scripts will negotiate separate pricing for the crowded class within four smaller indications: 1) rheumatoid arthritis;...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.